Actually the criteria have changed in the last week. It can be given as post exposure prophylaxis for anyone not vaccinated or at high risk of not mounting a sufficient immune response to the vaccine (immune suppressants, age, etc) with a known exposure prior to developing illness. For those with ongoing exposure (nursing homes, prison etc) it can be repeatedly monthly for as long as documented exposure continues. This is in addition to existing parameters Use in patients with severe disease has been found to be not beneficial and possibly harmful. For those with severe disease a drug called tociluzimab now has an EUA.
good to know they opened it up to known and ongoing exposure. Thanks.
I’d bet you already know about “Olumiant” baricitinib but I’ll put the link to a recent article up here for everyone. No clue how it compares to “Actemra” tociluzimab, or if “9 doctors out of 10 recommend...”: